Zimbabwe has turned down a significant US healthcare agreement valued at 367 million US dollars (£272m) over five years because of the United States' insistence on confidential biological samples.
The decision was revealed after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the deal was "lopsided".
An official spokesman has since stated that the US was requesting genetic material for scientific study and commercial gain while was unwilling to share the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued talks to secure a deal acceptable to all parties so the country's critical HIV programme can be sustained.
Broader Context
This development comes after a similar case in Kenya, where a high court suspended a related health funding agreement after concerns were filed about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to boost openness and accountability.
As per reports, Sixteen nations in Africa have so far agreed to similar health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to provide its biological resources and data for a long time, without any equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," he stated.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the end products would be available to our citizens if a future pandemic arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems already set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This mechanism is intended to guarantee that when a country provides its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how subsequent co-operation could be structured in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts expressed it recognised the official position, but urged that talks must proceed since a large portion of the nation's Aids initiatives relied on external financing.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," the group commented.
This impasse highlights the continuing tensions between accepting much-needed foreign assistance and protecting local interests in an ever more data-driven world.